Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 6/20 | 0.57 |
| ▸ | METAP2 | P50579 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cambendazole SCHEMBL44000 | 0.95 | METAP1 (0.48) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| Cambendazole SCHEMBL29409263 | 0.95 | METAP1 (0.48) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| Cambendazole SCHEMBL2895694 | 0.89 | METAP1 (0.55) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| Diethenofencarb SCHEMBL9055860 | 0.89 | HPSE (0.51) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| SCHEMBL3500748 | 0.85 | METAP1 (0.52) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| Mebendazole SCHEMBL2406875 | 0.84 | METAP1 (0.54) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| SCHEMBL4366074 | 0.81 | METAP1 (0.50) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| SCHEMBL4367982 | 0.81 | METAP1 (0.50) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| SCHEMBL11208569 | 0.79 | METAP1 (0.55) | METAP1METAP2SMN1; SMN2KDM4ETP53 | |
| SCHEMBL4367695 | 0.79 | METAP1 (0.48) | METAP1METAP2SMN1; SMN2KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247701-B1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180009754-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-3247701-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118638-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-0710105-A4 | SYNERGISTIC ANTHELMINTIC COMPOSITIONS | UNIV AUSTRALIAN (AU) | 1998-06-10 | — | — | EP | disclosed |
| EP-0710105-A1 | SYNERGISTIC ANTHELMINTIC COMPOSITIONS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1996-05-08 | — | — | EP | disclosed |
| WO-1994028887-A1 | SYNERGISTIC ANTHELMINTIC COMPOSITIONS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | CYP8B1, CYP2C8, CYP2B6 | METAP1 1022/4885METAP2 795/4885SMN1; SMN2 4838/4885 |
| US-20180009754-A1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | CYP8B1, CYP2C8, CYP2B6 | METAP1 1022/4885METAP2 795/4885SMN1; SMN2 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.